Lehi, Utah — October 6, 2025 — Leads & Copy — Halia Therapeutics, a clinical-stage biopharmaceutical company focused on anti-inflammatory therapies, has appointed Paul Jones as Chief Strategy Officer & GM, International Markets. Jones will accelerate GENMOR-AI, Halia’s AI platform for identifying genetic modifiers of disease, and strengthen the partnership with the Department of Health – Abu Dhabi.
CEO of Halia Therapeutics, David Bearss, Ph.D., stated Jones’s experience in genomics initiatives, including the UK’s 100,000 Genomes Project and the Emirati Genome Programme, makes him an asset to the leadership team.
Jones previously served as CEO of the Omics Centre of Excellence at M42 and Global Head of Population Genomics at Illumina. He also held roles at Cisco, Novartis, IMS Health, and PwC.
Halia’s APOE4 program in Alzheimer’s disease aims to identify resilience mechanisms using GENMOR-AI on genomic datasets to develop new therapies for neurodegeneration, metabolic disorders, cardiovascular disease, and cancer.
Paul Jones commented that Halia’s focus on genetic resilience positions the company to revolutionize drug discovery and patient outcomes through AI and global partnerships.
Halia Therapeutics is developing data-driven therapies targeting inflammatory pathways in diseases ranging from metabolic disorders to neurodegeneration and hematologic malignancies.
Contact:
Taylor Avei
Director of Business Development
Halia Therapeutics
info@haliatx.com
+1 (385) 355-4315
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com
Source: Halia Therapeutics
